Intellia, Cellex Team Up On New CAR-T Firm, Backed By Blackstone

 
• By Joseph Haas

Blackstone is providing $250m to combine Intellia’s gene editing and Cellex’s cell manufacturing capabilities in a new CAR-T company using Cellex subsidiary GEMoaB’s technology and pipeline as a foundation.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.
Blackstone is investing $250m in a new CAR-T firm using Intellia, Cellex technology

More from Financing

More from Business